Naval Daver presents findings of the ENHANCE-3 study at EHA2024 – AML Hub

AML Hub shared the following post on X:    .

“CONGRESS EHA2024 | Naval Daver

MD Anderson Cancer Center presents findings of the phase III ENHANCE-3 study (NCT05079230) evaluating efficacy and safety of magrolimab (vs placebo) in combination with azacitidine and venetoclax in pts with previously untreated AML ineligible for IC (N=378). Magrolimab, in comparison with placebo, led to:

• longer mOS (10.7 vs 14.1 mo, respectively),
• more deaths (44.4% vs 37.0%, respectively),
• similar CR rate within 6 cycles of treatment (41.3% vs 46.0%, respectively), and
• increased incidence of fatal AEs (19% vs 11.4%, respectively) and infections (11.1% vs 6.5%, respectively).

The study was stopped early due to crossing the prespecified futility boundary for OS.”

Source: AML Hub/X